All questionsIndication: Datroway (datopotamab deruxtecan-dlnk) in HR-positive HER2-negative breast cancer3 questions · 2 sourcesIndicationWhat is DATROWAY (datopotamab deruxtecan) approved to treat in HR-positive, HER2-negative breast cancer?“DATROWAY® (datopotamab deruxtecan-dlnk) is a Trop-2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with unresectable or metastatic, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC 1+ or IHC 2+/ISH−) breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.” (opens the source at this quote in a new tab)CopyFlagDrug namesWhat is the generic name of DATROWAY?“DATROWAY® (datopotamab deruxtecan-dlnk) for injection, for intravenous use” (opens the source at this quote in a new tab)CopyFlagTestingDoes DATROWAY require Trop-2 testing?“Trop-2 testing not required for DATROWAY.1” (opens the source at this quote in a new tab)CopyFlag